Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.70 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.70 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | AR | P10275 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15314447 | 0.87 | CYP1A2 (0.96) | CYP1A2CYP1A1CYP1B1AURKAPDPK1 | |
| SCHEMBL16805048 | 0.82 | CYP1A2 (0.53) | CYP1A2CYP1A1CYP1B1ALDH1A1AR | |
| SCHEMBL28634614 | 0.82 | CYP1A2 (0.53) | CYP1A2CYP1A1CYP1B1ALDH1A1AR | |
| SCHEMBL7386085 | 0.82 | CYP1A2 (0.79) | CYP1A2CYP1A1CYP1B1ALDH1A1AR | |
| SCHEMBL6813816 | 0.82 | ADORA2A (0.73) | CYP1A2CYP1A1CYP1B1AURKAPDPK1 | |
| SCHEMBL14413322 | 0.79 | CYP1A2 (0.74) | CYP1A2CYP1A1CYP1B1ALDH1A1AR | |
| SCHEMBL1104813 | 0.79 | CYP1A1 (0.56) | CYP1A2CYP1A1CYP1B1ALDH1A1KDM4E | |
| SCHEMBL16805035 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP1A1CYP1B1ALDH1A1AR | |
| SCHEMBL1358738 | 0.77 | RAB9A (0.61) | AURKAPDPK1TGFBR1ROCK1AURKB | |
| SCHEMBL20669851 | 0.77 | CYP1A2 (0.56) | CYP1A2CYP1A1CYP1B1ALDH1A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3359154-B1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2021-05-26 | — | — | EP | disclosed |
| US-20030055263-A1 | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2003006443-A2 | 2- 4-(NAPHTALIN-2-YL)-THIAZOL-2-YLAMINOCARBONYL BENZOIC ACID AND 2- 4-(NAPHTALIN-2-YL)-PYRIMIDIN-2-YLAMINOCARBONYL BENZOIC ACID AND ADDITIONAL COMPOUNDS SERVING AS TELOMERASE INHIBITORS FOR USE IN TUMOR THERAPY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055263-A1 | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production | TERT, POT1, REV1 | CYP1A2 732/4885CYP1A1 125/4885CYP1B1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.